Fuente: PubMed "hive" Allergol Immunopathol (Madr). 2026 Jan 1;54(1):172-176. doi: 10.15586/aei.v54i1.1459. eCollection 2026.ABSTRACTProgestogen hypersensitivity is a broad spectrum of disorders that may present with cutaneous manifestations such as urticaria and eczema-like lesions, as well as systemic symptoms including anaphylaxis. Anaphylaxis due to progestogen hypersensitivity is very rare but should be considered in cases of recurrent anaphylaxis, particularly in young female patients. The timing of symptoms is the leading hint, as endogenous progesterone-induced reactions typically occur during the luteal phase of the menstrual cycle. Exogenous progesterone exposure, such as through oral contraceptives or assisted reproductive technologies (e.g., in vitro fertilization), has also been reported to trigger similar reactions. Therapeutic options include systemic corticosteroids, antihistamine tablets to control symptoms, and antihormone agents aiming the ovulation suppression. In refractory patients who are unresponsive to medical therapy, surgical options such as oophorectomy may be considered. In this report, a case of progesterone-associated anaphylaxis, triggered by an intradermal progesterone test, is presented, and a successful symptom control was achieved through the high-dose omalizumab treatment. As an alternative treatment option, omalizumab can be safely used in cases of progestogen hypersensitivity, especially in young female patients planning pregnancy.PMID:41510936 | DOI:10.15586/aei.v54i1.1459